First-Line Treatment of Hypercalcemia

Hypercalcemia requires prompt pharmacological intervention to reduce serum calcium levels. This protocol covers first-line management, including dose considerations for patients with renal impairment.

Treatment Approach

First-line management centres on intravenous bisphosphonate therapy, with the specific agent and rate of administration determined by clinical factors including severity and renal function.

Full agent selection, dosing, and algorithm are available in the structured protocol — see below.

Clinical Goal

Serum calcium is expected to reach its nadir at 2–4 days following treatment initiation.

Instant Access to Structured Evidence-Based Regimens

References

Zoledronic acid 4 mg over 15 min
Pamidronate 30–90 mg (depending on severity of hypercalcaemia) at 20 mg/h
Ibandronic acid 2–4 mg
Give more slowly and consider dose reduction in renal impairment
Monitor serum calcium response: will reach nadir at 2–4 days

View source ↗